|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2010-10-15
|
|
pubmed:abstractText |
We conducted a first-in-human phase I study to determine the dose-limiting toxicity (DLT), evaluate the pharmacokinetic profile, and document any antitumor activity of NK012, a novel SN-38-incorporating micellar nanoparticle.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:DoiToshihikoT,
pubmed-author:Eguchi-NakajimaTakakoT,
pubmed-author:FuseNozomuN,
pubmed-author:HamaguchiTetsuyaT,
pubmed-author:KatoKenK,
pubmed-author:MatsumotoShin-ichiS,
pubmed-author:MatsumuraYasuhiroY,
pubmed-author:OhtsuAtsushiA,
pubmed-author:ShimadaYasuhiroY,
pubmed-author:TakanashiMasayaM,
pubmed-author:YamadaYasuhideY
|
|
pubmed:copyrightInfo |
©2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5058-66
|
|
pubmed:meshHeading |
pubmed-meshheading:20943763-Adult,
pubmed-meshheading:20943763-Aged,
pubmed-meshheading:20943763-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:20943763-Camptothecin,
pubmed-meshheading:20943763-Dose-Response Relationship, Drug,
pubmed-meshheading:20943763-Female,
pubmed-meshheading:20943763-Humans,
pubmed-meshheading:20943763-Male,
pubmed-meshheading:20943763-Middle Aged,
pubmed-meshheading:20943763-Nanoparticles,
pubmed-meshheading:20943763-Neoplasms
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors.
|
|
pubmed:affiliation |
Division of Gastrointestinal Oncology, National Cancer Center Hospital, Pharmaceutical Research Laboratories and Pharmaceutical Development, Nippon Kayaku Co Ltd, Tokyo, Japan. thamaguc@ncc.go.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I
|
